Biosimilars

Brain Cancer

HER2+ Breast Cancer

Breast Cancer

CAR T-cell Therapy

COVID-19

Disparities in Cancer Care

Colorectal Cancer

Gastric Cancer

Hepatocellular Carcinoma

Pancreatic Cancer

Gastrointestinal Cancer

Prostate Cancer

Urothelial Cancer

Genitourinary Cancers

Global Oncology

Ovarian Cancer

Gynecologic Oncology

Head & Neck Cancers

Chronic Lymphocytic Leukemia

Mantle Cell Lymphoma

Multiple Myeloma

Myeloproliferative Neoplasms

Non-Hodgkin Lymphoma

Hematologic Oncology

Immuno-Oncology

Lung Cancer

Melanoma & Skin Cancer

Oncology Business Management

Pediatric Oncology

Precision Medicine in Oncology®

Sarcomas

Supportive Care

Updated INDIGO data reveal that vorasidenib continues to showcase improved efficacy over placebo in patients with IDH1/2-mutated diffuse glioma.

Vorasidenib Shows Consistent Efficacy With Manageable Safety in IDH1/2-Mutant Diffuse Glioma

Tovorafenib generated durable drug holiday responses in pediatric patients with BRAF-altered relapsed/refractory low-grade glioma.

Tovorafenib Leads to Durable Off-Treatment Responses in Pediatric BRAF-Altered R/R Low-Grade Glioma

Early safety findings from the phase 2b RESTORE study (NCT03862430) of NanO2 plus radiation and temozolomide in newly diagnosed glioblastoma were shared.

NanO2 Plus Radiation/Temozolomide Is Under Exploration in Newly Diagnosed Glioblastoma

J. Bradley Elder, MD, discusses blinded early-safety data from a phase 2b trial of IGV-001 in patients with newly diagnosed glioblastoma.

Dr Elder on the Initial Safety Profile of IGV-001 in Newly Diagnosed Glioblastoma

News

OncClub

All Oncology News

Media

Insights

MedNews Week

OncChats

OncLive News Network®

OncLive TV

Peer Exchange

Podcasts

Rapid Readouts

Conferences

Conference Coverage

Conference Listing

Events

Giants of Cancer Care

CME/CE

Scientific Interchanges

State of the Science Summit / IPC

National Fellows Forum

Webinars

Partners

Publications

Resources

Interactive Tools

Biomarker Consortium

Subscribe

 
Kristi Rosa joined MJH Life Sciences in 2016 and has since held several positions within the company. She helped launch the rapidly growing infectious disease news resource 

. Prior to working at the company, she served as lead copywriter and marketing coordinator at The Strand Theater. Email: krosa@onclive.com

Articles

Jax DiEugenio joined MJH Life Sciences in 2024, first as an editorial intern before transitioning into a full-time assistant editor for 

. A recent College of New Jersey graduate, Jax majored in Journalism/ Professional Writing with minors in Public Health and Anthropology. He is also pursuing a Master's Degree in Public Health, concentrating on health communications.

Kyle Doherty joined MJH Life Sciences in 2021 and is the lead editor for 

as well as news and conference updates for OncLive.com. Email: kdoherty@mjhlifesciences.com

Zanidatamab scores approval for HER2+ biliary tract cancer, Versamune HPV is under exploration in HPV16+ head and neck squamous cell carcinoma, and more.

The OncFive: Top Oncology Articles for the Week of 11/17


Gina Mauro is your lead editorial contact for 

. She joined the company in 2015 and has held various positions on 

; she is also the on-air correspondent for 

. Prior to joining MJH Life Sciences, she worked at Gannett as a full-time reporter with the Asbury Park Press. Email: gmauro@onclive.com 

IGV-001, an autologous cell immunotherapy, demonstrated an acceptable safety profile in patients with newly diagnosed glioblastoma.

IGV-001 Showcases Positive Benefit-Risk Profile in Newly Diagnosed Glioblastoma

OncLive serves as the connection to oncology, including groundbreaking cancer news and interviews with top oncologists in multimedia formats.

Advertise

About OncLive

Editorial Board

MJH Life Sciences brands

Contact Us

Privacy

Terms & Conditions

Do Not Sell My Information

OncLive - Clinical Oncology News, Cancer Expert Insights

Facebook

LinkedIn

Youtube

Spotlight

In-person and virtual events just for HCPs

Specialty

1rem

primary

View

My Treatment Approach: Targeting Genetic Alterations in Tumors: Clinical Scenarios and Precision Oncology Approaches

Clinical

Overview of Tumor agnostic Treatment: Considerations for NGS Testing in Solid Tumors 

Videos

Insights into integrating tumor agnostic therapies for actionable genetic alterations across solid tumors. Renowned experts Dr. Vivek Subbiah, Dr. Karisa Schreck, and Dr. Rimas Lukas delve into pivotal clinical cases showcasing the identification and targeted treatment of BRAF and RET fusions. The in-depth discussion spotlights practical strategies for NGS testing, overcoming barriers to adoption, efficacy and safety data from landmark trials, sequencing of therapies, and the evolving landscape of precision oncology beyond current approvals. Gain invaluable clinical pearls for optimizing patient outcomes with tumor agnostic targeted agents in the community setting.

Experts discuss the importance of NGS testing for identifying actionable alterations like RET fusions in solid tumors and when to consider testing. 

Dr. Lukas presents a case of a young man with a BRAF-fused brain tumor treated with a MEK inhibitor. Explored tailored therapy targeting the underlying genetic alteration. 

Targeting RET Fusion in Brain Tumor

Dr. Schreck brings forward a compelling case of a teenage female with BRAF V600E mutant ganglioglioma. Witness how the identification of this specific genetic alteration paved the way for treated with targeted therapy.

BRAF V600E Mutant Ganglioglioma 

Experts discuss the challenges in adopting targeted therapies like BRAF/MEK inhibitors for BRAF-altered gliomas and gangliogliomas and strategies to facilitate their integration into practice.

Challenges in Adopting Targeted Therapies for BRAF Alterations

Dr. Subbiah and Dr. Lukas review the efficacy and safety data from key clinical trials like ROAR and MATC evaluating tumor agnostic therapies across different tumor types.

Efficacy and Safety of Tumor Agnostic Therapies  

Dr. Subbiah presents a pancreatic cancer case with PRKARA1A- RET fusion treated with selpercatinib in a clinical trial. 

PRKAR1A-RET Fusion in Pancreatic Cancer: Unlocking New Therapeutic Frontiers 

The panel discusses the impact of tumor agnostic approvals like BRAF/MEK inhibitors on the treatment landscape, unmet needs address and sequencing therapies like RET inhibitors in cancers like pancreatic cancer. 

Impact and Positioning of Tumor Agnostic Approvals  

The panelists provide their perspective on best practices for keeping up with the rapidly evolving RET fusion landscape and unmet needs to be addressed by future RET-targeted therapies beyond lung cancer. 

Overview of Tumor agnostic Treatment: Considerations for NGS Testing in Solid Tumors

EP: 1.Overview of Tumor agnostic Treatment: Considerations for NGS Testing in Solid Tumors

EP: 2.Targeting RET Fusion in Brain Tumor

EP: 3.BRAF V600E Mutant Ganglioglioma

EP: 4.Challenges in Adopting Targeted Therapies for BRAF Alterations

EP: 5.Efficacy and Safety of Tumor Agnostic Therapies

EP: 6.PRKAR1A-RET Fusion in Pancreatic Cancer: Unlocking New Therapeutic Frontiers

EP: 7.Impact and Positioning of Tumor Agnostic Approvals

EP: 8.Future Outlook for RET Fusion-Targeted Therapies

Latest Conference Coverage